Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis

Clinical Infectious Diseases

Volumn 60, Issue 4, 2015, Pages 549-556

  Thee, Stephanie ^a,b   Garcia Prats, Anthony J ^a   Draper, Heather R ^a   McIlleron, Helen M ^c   Wiesner, Lubbe ^c   Castel, Sandra ^c   Schaaf, H Simon ^a   Hesseling, Anneke C ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

children; MDR tuberculosis; moxifloxacin pharmacokinetics; moxifloxacin toxicity

Indexed keywords

MOXIFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADOLESCENT; AREA UNDER THE CURVE; BLOOD; CHILD; COMPLICATION; DRUG TOLERANCE; FEMALE; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PROSPECTIVE STUDY; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; CHILD; DRUG TOLERANCE; FEMALE; FLUOROQUINOLONES; HALF-LIFE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84922376416     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu868     Document Type: Article

References (40)

1. World Health Organization. Global tuberculosis report 2013. Geneva, Switzerland: WHO. WHO/HTM/TB/2013.11. Available at: http://www.who.int/tb/publications/global-report/en/. Accessed 26 June 2014.
2. Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrugresistant tuberculosis disease in children: systematic review and global estimates. Lancet 2014; 383:1572-9.
3. Raizada N, Sachdeva KS, Nair SA, et al. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB. PLoS One 2014; 9:e105346.
4. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update. (WHO/HTM/TB/2011.6). Available at: www.who.int/tb/challenges/mdr/programmatic- guidelines-for-mdrtb/en/. Accessed 26 July 2014.
5. Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002; 20:464-7.
6. Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012; 186:953-64.
7. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; 51:576-82.
8. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10:605-12.
9. Wang JY, Wang JT, Tsai TH, et al. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010; 14:65-71.
10. Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38:888-94.
11. Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007; 45:1001-7.
12. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52:852-7.
13. Zvada SP, Denti P, Geldenhuys H, et al. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine. Antimicrob Agents Chemother 2012; 56:4471-3.
14. Manika K, Chatzika K, Zarogoulidis K, Kioumis I. Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?. Eur Respir J 2012; 40:1051-3.
15. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an openlabel, randomised controlled phase 2 trial. Lancet Infect Dis 2013; 13:27-35.
16. Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 2001; 40(suppl 1):33-8.
17. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43(suppl B):83-90.
18. Moxifloxacin. Tuberculosis (Edinb) 2008; 88:127-31.
19. Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax 2014; 69:458-64.
20. Garazzino S, Scolfaro C, Raffaldi I, Barbui AM, Luccoli L, Tovo PA. Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience. Pediatr Pulmonol 2014; 49:372-6.
21. Watt KM, Massaro MM, Smith B, Cohen-Wolkowiez M, Benjamin DK Jr, Laughon MM. Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis. Pediatr Infect Dis J 2012; 31: 197-9.
22. Graham SM, Ahmed T, Amanullah F, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 2012; 205(suppl 2):S199-208.
23. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. Gyr A mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2012; 67:1088-93.
24. Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Ann Noninvasive Electrocardiol 2003; 8:343-51.
25. Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revisedWorld Health Organization recommendations. Antimicrob Agents Chemother 2011; 55:5560-7.
26. Schaaf HS, Willemse M, Cilliers K, et al. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med 2009; 7:19.
27. Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50:407-13.
28. Thee S, Garcia-Prats AJ, McIlleron HM, et al. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrugresistant tuberculosis in children. Antimicrob Agents Chemother 2014; 58:2948-51.
29. Anderson BJ, Holford NH. Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child 2013; 98: 737-44.
30. Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005; 1:447-71.
31. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 2004; 38:280-3.
32. Zhou J, Dong Y, Zhao X, et al. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 2000; 182:517-25.
33. Pinon M, Scolfaro C, Bignamini E, et al. Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin. Pediatrics 2010; 126:e1253-6.
34. Chauny JV, Lorrot M, Prot-Labarthe S, et al. Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases. Pediatr Infect Dis J 2012; 31:1309-11.
35. ChristW, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988; 10(suppl 1):S141-6.
36. Schaad UB. Will fluoroquinolones ever be recommended for common infections in children?. Pediatr Infect Dis J 2007; 26:865-7.
37. Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 2003; 22:1128-32.
38. Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect Dis 2012; 12:469-79.
39. Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis 2014; 18:912-8.
40. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59:122-6.